Gastroenterology Today Summer 2021
Gastroenterology Today Summer 2021
Gastroenterology Today Summer 2021
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
COMPANY NEWS<br />
COST EFFECTIVE & USER FRIENDLY<br />
SPECIMEN BIO-POUCH<br />
UN3373 Compliant Sample Packaging Solution<br />
The ShuttlePouch range of leak proof pouches is designed to carry<br />
individual 95kPa pressure differential certified blood or urine specimen<br />
tubes (or any similar sized specimen tube). They include absorbent<br />
material already inside the pouch for convenient compliance to UN3373<br />
packaging requirements.<br />
Each leak proof bio-pouch is printed with easy-to-follow instructions<br />
showing how to pack and seal the specimen tube. Simply add a rigid<br />
outer packaging box for a complete and compliant UN3373 solution.<br />
In addition, the 95kPa pressure differential compliant ShuttlePouch is<br />
certified for transport by air (IATA). With all the features described above,<br />
they can be used with any leak free tube for transport by road or air.<br />
The pouches also feature a transparent front so the tube and label are<br />
clearly visible. An easy to open tear area facilitates processing when the<br />
samples arrive at the lab.<br />
ShuttlePouch addresses the needs of customers, radically improving<br />
the user experience and reducing the cost of packing and shipping<br />
sample tubes compared with using conventional methods.<br />
The ShuttlePouch range is exclusive to Alpha Laboratories in the<br />
UK and Ireland, and provides a powerful, cost effective solution to the<br />
clinical and diagnostic market.<br />
Please visit www.alphalabs.co.uk/shuttlepouch for further information<br />
or contact Alpha Laboratories on 0800 38 77 32 or email marketing@<br />
alphalabs.co.uk<br />
BIOHIT’S TEST PANEL FOR STOMACH<br />
HEALTH BACKED BY FURTHER EVIDENCE<br />
GASTROENTEROLOGY TODAY - SUMMER <strong>2021</strong><br />
A recent study published by the research group of Professor<br />
Francesco Di Mario at Parma University, Italy, found a strong<br />
relationship between low levels of plasma Gastrin-17 (G-17)<br />
and the manifestation of gastro-oesophageal reflux disease<br />
(GORD). 1 These results add to the weight of evidence behind<br />
GastroPanel ® , a test produced by BIOHIT Oyj, that includes<br />
G-17 as one of three biomarkers used in combination with<br />
a Helicobacter pylori IgG assay to distinguish the stomach<br />
health of patients with gastrointestinal problems.<br />
GastroPanel is designed for the first-line diagnosis of H. pylori infection<br />
and atrophic gastritis in patients with dyspepsia or GORD. It is a<br />
non-invasive blood test that offers an easy way to check the stomach<br />
mucosa and gastric acid secretion in the patient. This can lead to an<br />
informed decision of whether further examination is needed – usually by<br />
gastroscopy – and ultimately to the early discovery and intervention of<br />
gastrointestinal disorders.<br />
Current UK guidelines recommend an H. pylori stool antigen test in the<br />
care pathway of patients with gastrointestinal problems. However, this<br />
test fails to show mucosal damage due to long-term infection, including<br />
gastric atrophy (GA) or gastric intestinal metaplasia (GIM), both of which<br />
are precursors to cancer. In addition to testing for H. pylori infection,<br />
GastroPanel tests for three stomach-specific biomarkers – pepsinogen I,<br />
pepsinogen II and G-17 – that provide more information than a stool test<br />
alone, helping to non-invasively identify patients at risk.<br />
Graham Johnson, Managing Director of BIOHIT HealthCare Ltd,<br />
commented: “The results from this study showed that GORD patients<br />
both in primary care, and those that had been referred, had statistically<br />
significant lower levels of G-17 compared with the dyspeptic patients. 1<br />
This confirms that the G-17 biomarker is a reliable predictor of GORD,<br />
and further extends the scope of gastric diseases detectable with the<br />
GastroPanel. We hope this helps to implement the wider use of the<br />
GastroPanel, which is a proven, cost-effective strategy in screening<br />
patients at risk of gastric cancer.”<br />
For more information visit www.biohithealthcare.co.uk/gastropanel.<br />
About BIOHIT Healthcare Ltd<br />
BIOHIT Healthcare Ltd (www.biohithealthcare.co.uk) is part of the<br />
Finnish public company, BIOHIT OYJ, which specialises in the<br />
development, manufacture and marketing of products and analysis<br />
systems for the early diagnosis and prevention of gastrointestinal<br />
diseases. The company’s many unique and patented diagnostic<br />
tests transform clinical practice and make screening, diagnosis and<br />
monitoring of gastrointestinal diseases efficient and cost effective.<br />
Non-invasive diagnostics are at the core of BIOHIT’s offering, making<br />
it the provider of choice for leading gastroenterologists and laboratory<br />
scientists worldwide.<br />
References<br />
1. Di Mario F, Crafa P, Franceschi M, et al. Low Levels of Gastrin 17 are Related<br />
with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD. JGLD<br />
[Internet]. 12Feb.<strong>2021</strong> [cited 11May<strong>2021</strong>];30(1):25-9. Available from:<br />
https://www.jgld.ro/jgld/index.php/jgld/article/view/2952<br />
30
Change language